Part 9
Charitable Prescription Drug Recycling Act

58-17b-901 Title.
This part is known as the "Charitable Prescription Drug Recycling Act."

Enacted by Chapter 405, 2016 General Session

58-17b-902 Definitions.
As used in this part:
(1) "Assisted living facility" means the same as that term is defined in Section 26-21-2.
(2) "Cancer drug" means a drug that controls or kills neoplastic cells and includes a drug used in chemotherapy to destroy cancer cells.
(3) "Charitable clinic" means a charitable nonprofit corporation that:
   (a) holds a valid exemption from federal income taxation issued under Section 501(a), Internal Revenue Code;
   (b) is exempt from federal income taxation under Section 501(c)(3), Internal Revenue Code;
   (c) provides, on an outpatient basis, for a period of less than 24 consecutive hours, to an individual not residing or confined at a facility owned or operated by the charitable nonprofit corporation:
      (i) advice;
      (ii) counseling;
      (iii) diagnosis;
      (iv) treatment;
      (v) surgery; or
      (vi) care or services relating to the preservation or maintenance of health; and
   (d) has a licensed outpatient pharmacy.
(4) "Charitable pharmacy" means an eligible pharmacy that is operated by a charitable clinic.
(5) "County health department" means the same as that term is defined in Section 26A-1-102.
(6) "Donated prescription drug" means a prescription drug that an eligible donor donates to an eligible pharmacy under the program.
(7) "Eligible donor" means a donor that donates a prescription drug from within the state and is:
   (a) a nursing care facility;
   (b) an assisted living facility;
   (c) a licensed intermediate care facility for people with an intellectual disability;
   (d) a manufacturer;
   (e) a pharmaceutical wholesale distributor;
   (f) an eligible pharmacy; or
   (g) a physician's office.
(8) "Eligible pharmacy" means a pharmacy that:
   (a) is registered by the division as eligible to participate in the program; and
   (b)
      (i) is licensed in the state as a Class A retail pharmacy; or
      (ii) is operated by:
         (A) a county;
         (B) a county health department;
(C) a pharmacy under contract with a county health department;
(D) the Department of Health, created in Section 26-1-4;
(E) the Division of Substance Abuse and Mental Health, created in Section 62A-15-103; or
(F) a charitable clinic.

(9) "Eligible prescription drug" means a prescription drug, described in Section 58-17b-904, that is not:
   (a) a controlled substance; or
   (b) a drug that can only be dispensed to a patient registered with the drug's manufacturer in accordance with federal Food and Drug Administration requirements.

(10) "Licensed intermediate care facility for people with an intellectual disability" means the same as that term is defined in Section 58-17b-503.

(11) "Medically indigent individual" means an individual who:
   (a)
      (i) does not have health insurance; and
      (ii) lacks reasonable means to purchase prescribed medications; or
   (b)
      (i) has health insurance; and
      (ii) lacks reasonable means to pay the insured's portion of the cost of the prescribed medications.

(12) "Nursing care facility" means the same as that term is defined in Section 26-18-501.

(13) "Physician's office" means a fixed medical facility that:
   (a) is staffed by a physician, physician's assistant, nurse practitioner, or registered nurse, licensed under Title 58, Occupations and Professions; and
   (b) treats an individual who presents at, or is transported to, the facility.

(14) "Program" means the Charitable Prescription Drug Recycling Program created in Section 58-17b-903.

(15) "Unit pack" means the same as that term is defined in Section 58-17b-503.

(16) "Unlawful conduct" means the same as that term is defined in Sections 58-1-501 and 58-17b-501.

(17) "Unprofessional conduct" means the same as that term is defined in Sections 58-1-501 and 58-17b-502.

Amended by Chapter 384, 2020 General Session

(1) There is created the Charitable Prescription Drug Recycling Program.
(2) The division, in consultation with the board, shall:
   (a) implement the program, on a statewide basis, to permit:
      (i) an eligible donor to transfer an eligible prescription drug to an eligible pharmacy for dispensing to a medically indigent individual; and
      (ii) an individual to transfer an eligible prescription drug to a physician's office:
         (A) that is an eligible donor; and
         (B) for transfer to an eligible pharmacy for dispensing to a medically indigent individual;
   (b) in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, make rules necessary to implement the program; and
   (c) provide technical assistance to entities that desire to participate in the program.

Amended by Chapter 384, 2020 General Session
58-17b-904 Criteria for eligible prescription drugs.  
An eligible pharmacy may not accept or dispense an unused prescription drug under the program unless the unused prescription drug:

(1)  
(a) is in a unit pack or the manufacturer’s sealed container; or  
(b) is an injectable medication;  

(2)  
(a) is unopened; or  
(b) is a cancer drug packaged in an unopened single-unit dose that has been removed from a multi-dose package;  

(3) is accepted and dispensed by the eligible pharmacy before:  
(a) a beyond use date that appears on the label;  
(b) the expiration date recommended by the manufacturer; or  
(c) a date, established by division rule for a specific prescription drug, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, that is later than the date in Subsection (3)(a) or (3)(b);  

(4)  
(a) is not adulterated or mislabeled; and  
(b) the pharmacist or licensed pharmacist technician accepting or dispensing the prescription drug does not have reason to believe that the prescription drug is adulterated or mislabeled.

Enacted by Chapter 405, 2016 General Session

58-17b-905 Participation in program -- Requirements -- Fees.  
(1) An eligible donor or an eligible pharmacy may participate in the program.  
(2) An eligible pharmacy:  
(a) shall comply with all applicable federal and state laws related to the storage and distribution of a prescription drug;  
(b) shall comply with all applicable federal and state laws related to the acceptance and transfer of a prescription drug, including 21 U.S.C. Chapter 9, Subchapter V, Part H, Pharmaceutical Distribution Supply Chain;  
(c) shall, before accepting or dispensing a prescription drug under the program, inspect each prescription drug to determine whether the prescription drug is an eligible prescription drug;  
(d) may dispense an eligible prescription drug to a medically indigent individual who:  
(i) is a resident of the state; and  
(ii) has a prescription issued by a practitioner;  
(e) may charge a handling fee, adopted by the division under Section 63J-1-504; and  
(f) may not accept, transfer, or dispense a prescription drug in violation of the federal Food, Drug, and Cosmetic Act, 21 U.S.C. Sec. 301 et seq.

Enacted by Chapter 405, 2016 General Session

58-17b-906 Liability of participating organizations and manufacturers.  
In the absence of bad faith or gross negligence, a person is not criminally or civilly liable for injury, death, or loss of property based solely on the fact that the person manufactured, provided, donated, accepted, or dispensed an eligible prescription drug under this part.
Enacted by Chapter 405, 2016 General Session

58-17b-907 Rules made by the division.

The rules made by the division under Subsection 58-17b-903(2)(b) shall include:

(1) registration requirements to establish the eligibility of a pharmacy to participate in the program;
(2) a formulary that includes all eligible prescription drugs approved by the federal Food and Drug Administration;
(3) standards and procedures for:
   (a) verifying whether a pharmacy or pharmacist participating in the program is licensed and in good standing with the board;
   (b) handling of an eligible prescription drug transferred in accordance with Subsection 58-17b-903(2) to an eligible pharmacy or a physician's office, including:
      (i) acceptance;
      (ii) identification, including redundant criteria for verification;
      (iii) documentation, under 21 U.S.C. Sec. 360eee-1, of transaction information, history, and statements;
      (iv) safe storage;
      (v) security;
      (vi) inspection;
      (vii) transfer; and
      (viii) dispensing;
   (c) a pharmacist or licensed pharmacy technician working in or consulting with a participating eligible donor;
   (d) disposition of a donated prescription drug that is a controlled substance;
   (e) record keeping regarding:
      (i) the eligible donor that donated each prescription drug;
      (ii) an individual who transferred an eligible prescription drug to a physician's office under Subsection 58-17b-903(2)(a)(ii);
      (iii) the identification and evaluation of a donated prescription drug by a pharmacist or licensed pharmacy technician; and
      (iv) the dispensing or disposition of a prescription drug;
   (f) determining the status of a medically indigent individual;
   (g) labeling requirements to:
      (i) ensure compliance with patient privacy laws relating to:
         (A) an individual who receives an eligible prescription drug; and
         (B) patient information that may appear on a donated prescription drug;
      (ii) clearly identify an eligible prescription drug dispensed under the program; and
      (iii) communicate necessary information regarding the manufacturer's recommended expiration date or the beyond use date; and
   (h) ensuring compliance with the requirements of this part;
(4) a process for seeking input from:
   (a) the Department of Health, created in Section 26-1-4, to establish program standards and procedures for assisted living facilities and nursing care facilities; and
   (b) the Division of Substance Abuse and Mental Health, created in Section 62A-15-103, to establish program standards and procedures for mental health and substance abuse clients; and
(5) the creation of a special training program that a pharmacist and a licensed pharmacy technician at an eligible pharmacy must complete before participating in the program.
58-17b-1001 Title.
This part is known as the "Epinephrine Auto-Injector and Stock Albuterol Act."

Enacted by Chapter 372, 2020 General Session

58-17b-1002 Definitions.
As used in this part:
(1) "Epinephrine auto-injector" means the same as that term is defined in Section 26-41-102.
(2) "Local health department" means the same as that term is defined in Section 26A-1-102.
(3) "Physician" means the same as that term is defined in Section 58-67-102.
(4) "Qualified adult" means the same as that term is defined in Section 26-41-102.
(5) "Qualified epinephrine auto-injector entity" means the same as that term is defined in Section 26-41-102.
(6) "Qualified stock albuterol entity" means the same as that term is defined in Section 26-41-102.
(7) "Stock albuterol" means the same as that term is defined in Section 26-41-102.

Enacted by Chapter 372, 2020 General Session

58-17b-1003 Voluntary participation.
This part does not create a duty or standard of care for a person to prescribe or dispense an epinephrine auto-injector or stock albuterol.

Enacted by Chapter 372, 2020 General Session

58-17b-1004 Authorization to dispense an epinephrine auto-injector and stock albuterol pursuant to a standing order.
(1) Notwithstanding any other provision of this chapter, a pharmacist or pharmacy intern may dispense an epinephrine auto-injector:
   (a)
      (i) to a qualified adult for use in accordance with Title 26, Chapter 41, Emergency Response for Life-threatening Conditions; or
      (ii) to a qualified epinephrine auto-injector entity for use in accordance with Title 26, Chapter 41, Emergency Response for Life-threatening Conditions;
   (b) pursuant to a standing prescription drug order made in accordance with Section 58-17b-1005;
   (c) without any other prescription drug order from a person licensed to prescribe an epinephrine auto-injector; and
   (d) in accordance with the dispensing guidelines in Section 58-17b-1006.
(2) Notwithstanding any other provision of this chapter, a pharmacist or pharmacist intern may dispense stock albuterol:
   (a)
(i) to a qualified adult for use in accordance with Title 26, Chapter 41, Emergency Response for Life-threatening Conditions; or
(ii) to a qualified stock albuterol entity for use in accordance with Title 26, Chapter 41, Emergency Response for Life-threatening Conditions;
(b) pursuant to a standing prescription drug order made in accordance with Section 58-17b-1005;
(c) without any other prescription drug order from a person licensed to prescribe stock albuterol; and
(d) in accordance with the dispensing guidelines in Section 58-17b-1006.

Enacted by Chapter 372, 2020 General Session

Effective 7/1/2020
58-17b-1005 Standing prescription drug orders for epinephrine auto-injectors and stock albuterol.

(1) A physician acting in the physician's capacity as an employee of the Department of Health or as a medical director of a local health department may issue a standing prescription drug order authorizing the dispensing of an epinephrine auto-injector under Section 58-17b-1004 in accordance with a protocol that:
(a) requires the physician to specify the persons, by professional license number, authorized to dispense the epinephrine auto-injector;
(b) requires the physician to review at least annually the dispensing practices of those authorized by the physician to dispense the epinephrine auto-injector;
(c) requires those authorized by the physician to dispense the epinephrine auto-injector to make and retain a record of each dispensing, including:
   (i) the name of the qualified adult or qualified epinephrine auto-injector entity to whom the epinephrine auto-injector is dispensed;
   (ii) a description of the epinephrine auto-injector dispensed; and
   (iii) other relevant information; and
(d) is approved by the division by administrative rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, in collaboration with the Physicians Licensing Board created in Section 58-67-201 and the Board of Pharmacy.

(2) A physician acting in the physician's capacity as an employee of the Department of Health or as a medical director of a local health department may issue a standing prescription drug order authorizing the dispensing of the stock albuterol under Section 58-17b-1004 in accordance with a protocol that:
(a) requires the physician to specify the persons, by professional license number, authorized to dispense the stock albuterol;
(b) requires the physician to review at least annually the dispensing practices of those authorized by the physician to dispense the stock albuterol;
(c) requires those authorized by the physician to dispense the stock albuterol to make and retain a record of each dispensing, including:
   (i) the name of the qualified adult or qualified stock albuterol entity to whom the stock albuterol is dispensed;
   (ii) a description of the stock albuterol dispensed; and
   (iii) other relevant information; and
(d) is approved by the division by administrative rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, in collaboration with the Physicians Licensing Board created in Section 58-67-201 and the board.
Enacted by Chapter 372, 2020 General Session

**Effective 7/1/2020**

**58-17b-1006 Guidelines for dispensing an epinephrine auto-injector and stock albuterol.**

(1) A pharmacist or pharmacy intern who dispenses an epinephrine auto-injector under this part shall, at a minimum, provide patient counseling to the qualified adult or qualified epinephrine auto-injector entity to whom the epinephrine auto-injector is dispensed regarding:
   (a) the appropriate administration and storage of the epinephrine auto-injector;
   (b) potential side effects and risks of the epinephrine auto-injector; and
   (c) when to seek emergency medical attention.

(2) A pharmacist or pharmacy intern who dispenses stock albuterol under this part shall, at a minimum, provide patient counseling to the qualified adult or qualified stock albuterol entity to whom the stock albuterol is dispensed regarding:
   (a) the appropriate administration and storage of the stock albuterol;
   (b) potential side effects and risks of the stock albuterol; and
   (c) when to seek emergency medical attention.

Enacted by Chapter 372, 2020 General Session

**Effective 7/1/2020**

**58-17b-1007 Limited civil liability.**

(1) A physician who issues a standing prescription drug order in accordance with Subsection 58-17b-1005(1) is not liable for any civil damages for acts or omissions resulting from the dispensing of an epinephrine auto-injector under this part.

(2) A physician who issues a standing prescription drug order in accordance with Subsection 58-17b-1005(2) is not liable for any civil damages for acts or omissions resulting from the dispensing of stock albuterol under this part.

Enacted by Chapter 372, 2020 General Session